Study #2024-1378
EXActDNA-003: breast cancer clinical validation study to predict recurrence of high-risk early breast cancer treated with neoadjuvant therapy using a bespoke circulating tumor DNA assay to detect molecular residual disease (NSABP B-64)
MD Anderson Study Status
Enrolling
Treatment Agent
Diagnostic Test: ctDNA MRD test
Description
The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer
Study phase:
Physician name:
Vicente Valero
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-844-580-2777
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.